6
Participants
Start Date
January 9, 2023
Primary Completion Date
February 22, 2023
Study Completion Date
February 22, 2023
ALRN-6924
ALRN-6924 administered in every chemotherapy treatment cycle as an IV infusion over 1 hour on Days 0 (approximately 18 hours prior to chemotherapy administration), 1 (approximately 1 hour prior to chemotherapy administration), and 2 (approximately 24 hours after the second infusion of ALRN-6924).
TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)
TAC will be administered as an IV infusion on Day 1 of every 3-week treatment cycle
KOC (Complex Oncology Center) Plovdiv, Plovdiv
MBAL University Hospital OOD, Panagyurishte
"Kliničko bolnički centar Bežanijska kosa", Belgrade
Pennsylvania Cancer Specialists & Resesrach Institute, Gettysburg
Oncology Institute of Vojvodina, Kamenitz
Regional Medical Oncolgy Center, Wilson
Southern Oncology Specialists, Huntersville
Oncology and Hematology Associates of West Broward, Tamarac
Univerzitetski Klinički centar Kragujevac, Kragujevac
Gabrail Cancer Center, Canton
University Clinical Center of the Republic of Srpska, Banja Luka
Clinical Center University of Sarajevo, Oncology Clinic, Sarajevo
University Clinical Center Tuzla, Tuzla
University Clinical Hospital Mostar, Mostar
Lead Sponsor
Aileron Therapeutics, Inc.
INDUSTRY